Benitec Biopharma (BNTC) Competitors $10.89 -0.60 (-5.22%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$10.87 -0.02 (-0.18%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BNTC vs. GLUE, AGIO, VIR, OCS, and NTLAShould you buy Benitec Biopharma stock or one of its competitors? MarketBeat compares Benitec Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Benitec Biopharma include Monte Rosa Therapeutics (GLUE), Agios Pharmaceuticals (AGIO), Vir Biotechnology (VIR), Oculis (OCS), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. BNTC vs. GLUEBNTC vs. AGIOBNTC vs. VIRBNTC vs. OCSBNTC vs. NTLAHow does Benitec Biopharma compare to Monte Rosa Therapeutics?Monte Rosa Therapeutics (NASDAQ:GLUE) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Do analysts recommend GLUE or BNTC? Monte Rosa Therapeutics currently has a consensus price target of $32.50, indicating a potential upside of 80.46%. Benitec Biopharma has a consensus price target of $27.00, indicating a potential upside of 147.93%. Given Benitec Biopharma's higher probable upside, analysts clearly believe Benitec Biopharma is more favorable than Monte Rosa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monte Rosa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67Benitec Biopharma 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Do insiders & institutionals believe in GLUE or BNTC? 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Benitec Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media prefer GLUE or BNTC? In the previous week, Benitec Biopharma had 3 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 6 mentions for Benitec Biopharma and 3 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 1.17 beat Benitec Biopharma's score of 0.58 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Benitec Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is GLUE or BNTC more profitable? Benitec Biopharma has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -302.69%. Benitec Biopharma's return on equity of -34.82% beat Monte Rosa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Monte Rosa Therapeutics-302.69% -40.99% -25.94% Benitec Biopharma N/A -34.82%-34.11% Which has more volatility & risk, GLUE or BNTC? Monte Rosa Therapeutics has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market. Which has better earnings & valuation, GLUE or BNTC? Benitec Biopharma has lower revenue, but higher earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonte Rosa Therapeutics$42.95M35.42-$38.63M-$1.48N/ABenitec Biopharma$80K4,675.89-$37.92M-$1.14N/A SummaryMonte Rosa Therapeutics and Benitec Biopharma tied by winning 8 of the 16 factors compared between the two stocks.How does Benitec Biopharma compare to Agios Pharmaceuticals?Agios Pharmaceuticals (NASDAQ:AGIO) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends. Is AGIO or BNTC more profitable? Benitec Biopharma has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -639.84%. Agios Pharmaceuticals' return on equity of -34.11% beat Benitec Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Agios Pharmaceuticals-639.84% -34.11% -31.66% Benitec Biopharma N/A -34.82%-34.11% Do analysts recommend AGIO or BNTC? Agios Pharmaceuticals presently has a consensus target price of $41.56, indicating a potential upside of 47.31%. Benitec Biopharma has a consensus target price of $27.00, indicating a potential upside of 147.93%. Given Benitec Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Benitec Biopharma is more favorable than Agios Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agios Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.45Benitec Biopharma 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Do insiders and institutionals believe in AGIO or BNTC? 52.2% of Benitec Biopharma shares are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by insiders. Comparatively, 4.8% of Benitec Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, AGIO or BNTC? Agios Pharmaceuticals has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Which has higher valuation & earnings, AGIO or BNTC? Benitec Biopharma has lower revenue, but higher earnings than Agios Pharmaceuticals. Benitec Biopharma is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgios Pharmaceuticals$54.03M31.05-$412.78M-$7.25N/ABenitec Biopharma$80K4,675.89-$37.92M-$1.14N/A Does the media prefer AGIO or BNTC? In the previous week, Agios Pharmaceuticals and Agios Pharmaceuticals both had 6 articles in the media. Benitec Biopharma's average media sentiment score of 0.58 beat Agios Pharmaceuticals' score of 0.23 indicating that Benitec Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Benitec Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBenitec Biopharma beats Agios Pharmaceuticals on 8 of the 14 factors compared between the two stocks.How does Benitec Biopharma compare to Vir Biotechnology?Benitec Biopharma (NASDAQ:BNTC) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends. Does the media favor BNTC or VIR? In the previous week, Vir Biotechnology had 1 more articles in the media than Benitec Biopharma. MarketBeat recorded 7 mentions for Vir Biotechnology and 6 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 0.58 beat Vir Biotechnology's score of -0.04 indicating that Benitec Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Vir Biotechnology 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts recommend BNTC or VIR? Benitec Biopharma currently has a consensus target price of $27.00, suggesting a potential upside of 147.93%. Vir Biotechnology has a consensus target price of $20.25, suggesting a potential upside of 130.90%. Given Benitec Biopharma's higher possible upside, analysts clearly believe Benitec Biopharma is more favorable than Vir Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Benitec Biopharma 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63Vir Biotechnology 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Is BNTC or VIR more profitable? Benitec Biopharma has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Benitec Biopharma's return on equity of -34.82% beat Vir Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Benitec BiopharmaN/A -34.82% -34.11% Vir Biotechnology -638.88%-53.31%-41.76% Which has more volatility and risk, BNTC or VIR? Benitec Biopharma has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market. Which has better earnings & valuation, BNTC or VIR? Benitec Biopharma has higher earnings, but lower revenue than Vir Biotechnology. Benitec Biopharma is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBenitec Biopharma$80K4,675.89-$37.92M-$1.14N/AVir Biotechnology$68.56M21.57-$437.99M-$3.13N/A Do insiders and institutionals hold more shares of BNTC or VIR? 52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 4.8% of Benitec Biopharma shares are held by insiders. Comparatively, 2.9% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryBenitec Biopharma beats Vir Biotechnology on 9 of the 17 factors compared between the two stocks.How does Benitec Biopharma compare to Oculis?Oculis (NASDAQ:OCS) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings. Do analysts prefer OCS or BNTC? Oculis presently has a consensus price target of $45.71, indicating a potential upside of 62.86%. Benitec Biopharma has a consensus price target of $27.00, indicating a potential upside of 147.93%. Given Benitec Biopharma's higher possible upside, analysts plainly believe Benitec Biopharma is more favorable than Oculis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75Benitec Biopharma 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Which has preferable earnings & valuation, OCS or BNTC? Benitec Biopharma has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOculis$1.45M1,122.41-$119.44M-$2.13N/ABenitec Biopharma$80K4,675.89-$37.92M-$1.14N/A Which has more risk and volatility, OCS or BNTC? Oculis has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market. Does the media refer more to OCS or BNTC? In the previous week, Oculis had 20 more articles in the media than Benitec Biopharma. MarketBeat recorded 26 mentions for Oculis and 6 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 0.58 beat Oculis' score of 0.55 indicating that Benitec Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Benitec Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of OCS or BNTC? 22.3% of Oculis shares are owned by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are owned by institutional investors. 4.8% of Benitec Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is OCS or BNTC more profitable? Benitec Biopharma has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Benitec Biopharma's return on equity of -34.82% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Oculis-8,460.67% -56.78% -45.62% Benitec Biopharma N/A -34.82%-34.11% SummaryBenitec Biopharma beats Oculis on 11 of the 16 factors compared between the two stocks.How does Benitec Biopharma compare to Intellia Therapeutics?Intellia Therapeutics (NASDAQ:NTLA) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings. Does the media prefer NTLA or BNTC? In the previous week, Intellia Therapeutics had 18 more articles in the media than Benitec Biopharma. MarketBeat recorded 24 mentions for Intellia Therapeutics and 6 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 0.58 beat Intellia Therapeutics' score of 0.32 indicating that Benitec Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Benitec Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in NTLA or BNTC? 88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are held by institutional investors. 3.1% of Intellia Therapeutics shares are held by company insiders. Comparatively, 4.8% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts rate NTLA or BNTC? Intellia Therapeutics currently has a consensus price target of $20.25, suggesting a potential upside of 59.57%. Benitec Biopharma has a consensus price target of $27.00, suggesting a potential upside of 147.93%. Given Benitec Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Benitec Biopharma is more favorable than Intellia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intellia Therapeutics 3 Sell rating(s) 10 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.35Benitec Biopharma 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Is NTLA or BNTC more profitable? Benitec Biopharma has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -597.04%. Benitec Biopharma's return on equity of -34.82% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intellia Therapeutics-597.04% -57.47% -46.24% Benitec Biopharma N/A -34.82%-34.11% Which has more risk & volatility, NTLA or BNTC? Intellia Therapeutics has a beta of 1.93, meaning that its share price is 93% more volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market. Which has stronger valuation and earnings, NTLA or BNTC? Benitec Biopharma has lower revenue, but higher earnings than Intellia Therapeutics. Benitec Biopharma is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntellia Therapeutics$67.67M26.20-$412.69M-$3.54N/ABenitec Biopharma$80K4,675.89-$37.92M-$1.14N/A SummaryBenitec Biopharma beats Intellia Therapeutics on 10 of the 17 factors compared between the two stocks. Get Benitec Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BNTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BNTC vs. The Competition ExportMetricBenitec BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$394.73M$3.31B$6.25B$12.29BDividend YieldN/A2.34%2.80%5.32%P/E Ratio-9.5518.1320.6425.23Price / Sales4,675.89289.87554.8579.36Price / CashN/A55.2727.4837.30Price / Book2.946.579.666.63Net Income-$37.92M$24.35M$3.56B$335.59M7 Day Performance-8.02%-2.53%-1.65%-1.20%1 Month Performance-22.66%-3.55%-2.60%-1.16%1 Year Performance-22.10%53.51%30.07%28.10% Benitec Biopharma Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BNTCBenitec Biopharma1.8875 of 5 stars$10.89-5.2%$27.00+147.9%-19.9%$394.73M$80KN/A20Earnings ReportAnalyst UpgradeGLUEMonte Rosa Therapeutics2.8194 of 5 stars$19.34-1.2%$32.80+69.6%+352.5%$1.63B$123.67MN/A90Positive NewsAGIOAgios Pharmaceuticals3.096 of 5 stars$27.21-1.3%$41.56+52.7%-3.3%$1.62B$54.03MN/A390Positive NewsVIRVir Biotechnology2.97 of 5 stars$10.01-1.7%$20.38+103.5%+90.7%$1.61B$68.56MN/A580OCSOculis3.1303 of 5 stars$27.75-1.8%$43.86+58.0%+57.3%$1.61B$1.45MN/A2Analyst Forecast Related Companies and Tools Related Companies GLUE Alternatives AGIO Alternatives VIR Alternatives OCS Alternatives NTLA Alternatives PGEN Alternatives BCAX Alternatives HROW Alternatives DMRA Alternatives IMTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BNTC) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Benitec Biopharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Benitec Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
